Deazaneplanocin A Is a Promising Drug to Kill Multiple Myeloma Cells in Their Niche. Gaudichon J et al. PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment. Borsi E et al. Exp Cell Res. 2014 Sep 25. pii: S0014-4827(14)00423-6. doi: 10.1016/j.yexcr.2014.09.018.…
DetailsA phase 1/2 study of an adjuvanted varicella-zoster virus subunit candidate vaccine in adult autologous hematopoietic stem-cell transplant recipients. Stadtmauer EA et al. Blood. 2014 Sep 18. pii: blood-2014-04-573048. [Epub ahead of print]. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of…
DetailsHarnessing the immune system for cancer therapy. Smith EL et al. Curr Opin Oncol. 2014 Sep 23. [Epub ahead of print]. CCN1: a sticky issue in myeloma. Roodman GD. Blood. 2014 Sep 25;124(13):2006-8. doi: 10.1182/blood-2014-08-592303. Appraising Myc involvement in high risk myeloma. Kastritis E et al. Leuk Lymphoma. 2014 Sep 26:1-5. [Epub ahead of print].…
DetailsSerum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Engels EA et al. Bone Marrow Transplant. 2014 Sep 29. doi: 10.1038/bmt.2014.213. [Epub ahead of print]. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Kashyap R et al. Asia Pac J Clin Oncol. 2014 Sep 22.…
DetailsLenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print]. Bortezomib, thalidomide and…
DetailsDiffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print]. Immunophenotypic analysis of…
DetailsIncidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Hultcrantz M et al. Cancer Med. 2014 Aug 26. doi: 10.1002/cam4.316. [Epub ahead of print]. Bortezomib in multiple myeloma: systematic review and clinical considerations. Kouroukis TC et al. Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Novel Agents In Cns Myeloma Treatment.…
Details11C-PiB PET/CT in Nasopharyngeal Amyloidosis Associated with Multiple Myeloma. Ishimura M et al. Clin Nucl Med. 2014 Aug 19. [Epub ahead of print]. Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. Napolitano M et al. Leuk Lymphoma. 2014 Aug 20:1-10. [Epub ahead of…
DetailsOral therapy for multiple myeloma: ixazomib arriving soon.Moreau P. Blood. 2014 Aug 14;124(7):986-7. doi: 10.1182/blood-2014-06-581611.A multicenter, open-label phase II study of recombinant CPT (circularly permuted TRAIL) plus thalidomide in patients with relapsed and/or refractory multiple myeloma.Geng C et al. Am J Hematol. 2014 Aug 4. doi: 10.1002/ajh.23822. [Epub ahead of print].Novel AKT inhibitor afuresertib shows…
DetailsPro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies. Smolewski P et al. Eur J Cancer. 2014 Aug 18. pii: S0959-8049(14)00873-9. doi: 10.1016/j.ejca.2014.07.021. [Epub ahead of print]. Cell membrane associated free kappa light chains are found on a subset of tonsil and in…
Details